Image: Bigstock
Moderna (MRNA - Free Report) stock has surged as much as 10% in Friday's trading session, reaching a fresh 52-week high of $267 a share after the biotechnology giant delivered much stronger-than-expected Q3 results.
The rally comes as investors increasingly gravitate toward healthcare stocks for defensive safety amid the broader technology selloff, with industry giants AbbVie (ABBV - Free Report) and Eli Lilly (LLY - Free Report) recently reaching new highs as well.
However, with Moderna stock extending an extraordinary year-to-date rally of nearly 800%, investors may be wondering whether to chase the momentum or await a more attractive entry point.
Much of MRNA's remarkable surge has been fueled by positive Phase 3 melanoma trial results for its personalized cancer vaccine being developed with Merck (MRK - Free Report), alongside improving financial performance and optimism surrounding its expanding vaccine portfolio.
Image Source: Zacks Investment Research
Moderna's Q3 Earnings Crush Expectations
Moderna reported Q3 earnings of $0.38 per share, crushing expectations that called for a loss of $1.10 per share by 134% and reversing a loss of $0.51 in the year-ago quarter.
Quarterly revenue jumped 29% year over year to $1.31 billion, comfortably surpassing estimates of $889 million. Growth was primarily driven by stronger international COVID-19 vaccine sales, supported by long-term government supply agreements.
Encouragingly, Moderna generated $162 million in net income compared with a $200 million loss a year earlier, aided by a 27% reduction in research and development (R&D) expenses.
Image Source: Zacks Investment Research
Moderna Provides Upbeat Guidance
Adding to the optimism, Moderna raised its full-year 2026 revenue growth outlook to 15%-25%, up from its previous forecast of up to 10% growth and ahead of Wall Street’s expectations of $2.1 billion in annual sales or 8% growth (Current Year Below).
Management also lowered its R&D spending outlook to approximately $2.7 billion from $2.9 billion.
Image Source: Zacks Investment Research
Moderna's Valuation Raises Concerns After Massive Rally
Despite its impressive operating improvements, Moderna's valuation presents significant risks following its extraordinary YTD rally.
To that point, MRNA commands a market capitalization exceeding $100 billion and trades near 40X forward sales, an exceptionally rich premium for a biotechnology company still working toward sustainable profitability.
With Moderna remaining unprofitable over the last 12 months, traditional forward P/E comparisons are less useful, making its elevated price-to-sales multiple particularly concerning.
While the company's expanding pipeline offers substantial long-term potential, much of that optimism may already be reflected in its stock price.
Image Source: Zacks Investment Research
Bottom Line: Buy, Hold, or Sell MRNA?
Moderna currently lands a Zacks Rank #3 (Hold), suggesting investors may want to avoid chasing the post-earnings spike despite the company's impressive Q3 results and improved outlook.
With MRNA extending its massive year-to-date rally, better buying opportunities could certainly be ahead. However, Moderna stock could become an ideal buy-the-dip target on a sharp pullback, particularly if its improving fundamentals and promising pipeline remain intact.
Comments
Log in or sign up to join the conversation.